Real-World Progression-Free Survival with Erlotinib versus Osimertinib in EGFR L858R+T790M Compound Mutation Non-Small Cell Lung Cancer: An Exploratory Analysis of the MSK-CHORD Dataset
This exploratory analysis of the MSK-CHORD dataset suggests that, unlike in L858R-only or T790M-only contexts where osimertinib is superior or equivalent, the EGFR L858R+T790M compound mutation in non-small cell lung cancer may represent a distinct pharmacological entity where erlotinib numerically outperforms osimertinib, warranting prospective validation.